Tuesday, March 17, 2026

THE CALIBER OF SUCCESSION : Why Ju Ae’s Finger On The Trigger Is A Message To The World

North Korean media highlights Ju-ae's military involvement, suggesting her emergence as a future leader alongside Kim Jong Un.

LS Cable Secures 700 Million KRW High-Voltage Cable Contract in the U.S.: What This Means for the Future

LS Cable & System secures a $482M contract in the U.S. for high-voltage cables, involving extensive collaboration with its domestic division.

TikToker Blasts Trump Token Dinner: “Like Walmart Steak, but Worse”

Trump hosted a dinner for Trump Token holders, but attendees criticized the food and his speech as disappointing and empty.

Tag: clinical trials

Revolutionary mRNA Cancer Treatment Shows 49% Survival Improvement: What You Need to Know

A study shows mRNA-based cancer treatments significantly improve survival rates, marking a breakthrough in precision therapy for melanoma.

Unlocking the Future of Healthcare: How Adaptive Clinical Trials Can Transform Regenerative Medicine in Asia

The article discusses South Korea's efforts to ease regulations on regenerative medicine to improve patient access while addressing significant challenges.

Unlocking the Future: How Neuracle Science’s NS101 is Set to Revolutionize Alzheimer’s Treatment by 2030

Neuracle Science aims for a KOSDAQ listing and focuses on developing NS101 for neurological diseases, attracting global interest.

Nesuparib vs. Traditional Treatments: Will This New Dual-Target Cancer Drug Change the Game for Ovarian Cancer?

Onconic Therapeutics advances Nesuparib into Phase 2 trials for ovarian cancer, aiming to validate a novel re-maintenance therapy approach.

CKDB-501A vs. Botox: Can CKD BiO’s New Botulinum Toxin Compete in China’s Booming Market?

Jongkundang Bio has successfully completed Phase 3 trials in China's botulinum toxin market, signaling global expansion.

Revolutionizing Pharma: How LG CNS’s Agentic AI is Set to Transform Drug Development in South Korea

LG CNS expands its AI Transformation business into pharma, enhancing drug development with AI-driven platforms and automation services.

Botox Faces New Challenger: Chong Kun Dang’s Toxin Shows Non-Inferiority in China Study

Chong Kun Dang's CKDB-501A shows non-inferiority to Botox in Phase 3 trials for treating glabellar lines, with promising safety data.

Korea Clears New Probiotic Claim: hy’s HY7017 Shows Immune Gains in Human Trials

hy's probiotic strain HY7017 has been approved for immune enhancement, adding to its portfolio of nine recognized ingredients.

NK Cell Cancer Therapies Move Closer to Market as Matica BioLabs Partners With Ingenium

CHA Biotech's Matica BioLabs partners with Ingenium Therapeutics for NK cell therapy production, targeting cancer treatment advancements.

ABL206: First-in-Class Dual Antibody Drug Conjugate Approved for Clinical Trials in the U.S. – What This Means for Cancer Treatment

ABL Bio and Neok Bio received FDA approval for ABL206, a dual-antibody ADC, marking a key milestone in their clinical development efforts.

Is DD01 the Future of MASH Treatment? Insights from D&D Pharmatech’s JP Morgan Presentation

D&D Pharmatech's CEO highlights growth in K-bio at JPM Healthcare Conference, unveiling promising drug data and future plans for clinical trials.

Chong Kun Dang Wins European Phase 1 Approval for Dupixent Biosimilar: Advancing CKD-706’s Global Development

Chong Kun Dang's CKD-706 biosimilar for Dupixent received Phase 1 trial approval in Europe, aiming to expand treatment options for inflammatory diseases.

2026: South Korea’s Advanced Regenerative Medicine R&D Investment Expands – What You Need to Know!

The Ministry of Health and Welfare aims to boost investments in advanced regenerative medicine R&D and improve research infrastructure in South Korea.

HK inno.N’s New Drug K-CAB Applies for U.S. FDA Approval: How Innovative Is the P-CAB Therapy?

HK inno.N's K-Cap for GERD has entered the U.S. approval process, showing superior results in clinical trials over existing treatments.

Top News

- Our Sponsors Ad -

Follow us